Estudo randomizado | Trametinibe melhora a sobrevida livre de progressão em comparação ao tratamento padrão em pacientes com recidiva de câncer de ovário seroso de baixo grau.

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial – The Lancet

Comunicado de imprensa: Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma – M. D. Anderson Cancer Center

Comentário no Twitter

Trial findings suggest MEK inhibitor, trametinib, represents new standard-of-care option for patients with recurrent low-grade serous carcinoma. https://t.co/69glZZdrZF pic.twitter.com/UHeccCj1Rn

— The Lancet (@TheLancet) February 10, 2022